Regular biography
Dr. Vladimir Radchenko is a leading researcher in the field of nuclear chemistry and medical isotope production. He is currently affiliated with TRIUMF, Canada's national laboratory for particle and nuclear physics, where he works on the development of medical isotopes and radionuclide generators for use in nuclear medicine. His research focuses on the production, separation, and application of radionuclides for diagnostic and therapeutic purposes, particularly in the context of targeted alpha therapy and theranostic applications. Dr. Radchenko has made significant contributions to the development of new ligands for the chelation of actinium-225, a promising radionuclide for cancer therapy. He has also been involved in the production of isotopes such as 44Ti, 111Ag, and 103Ru, which are used in various therapeutic and diagnostic applications. His work has been published in numerous high-impact journals, including *Angewandte Chemie International Edition*, *Analytical Chemistry*, *Talanta*, and *Nuclear Medicine and Biology*. Dr. Radchenko is also actively involved in collaborative projects with academic institutions and industry partners to advance the development of new radiopharmaceuticals and improve the efficiency of isotope production processes.